Literature DB >> 28610665

Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis.

Guillermo Suarez-Cuartin1, Alex Smith2, Hani Abo-Leyah2, Ana Rodrigo-Troyano1, Lidia Perea3, Silvia Vidal3, Vicente Plaza1, Thomas C Fardon2, Oriol Sibila1, James D Chalmers4.   

Abstract

BACKGROUND: Identification of chronic Pseudomonas aeruginosa (PA) infection is important in the management of bronchiectasis, but requires repeated sputum sampling. We hypothesized that serum anti-PA IgG antibodies could diagnose chronic PA infection at a single visit.
METHODS: Clinically stable bronchiectasis patients were studied prospectively. Chronic PA infection was defined as 2 or more positive sputum samples at least 3 months apart and/or failure to clear PA following eradication treatment. Baseline serum anti-PA IgG was determined by a validated ELISA kit.
RESULTS: A total of 408 patients were included. Sixty of them (14.7%) had chronic PA infection and had higher anti-PA IgG levels (median 6.2 vs. 1.3 units, p < 0.001). Antibody levels showed direct significant correlations with exacerbation frequency, the bronchiectasis severity index and sputum inflammatory markers. Fifty-seven patients with chronic PA infection had a positive test, giving 95% sensitivity, 74.4% specificity and AUROC of 0.87. During follow-up, 38 patients had a new PA isolation. Eradication at 12 months was achieved in 89.5% of subjects with a negative antibody test and 15.8% of patients with a positive test.
CONCLUSIONS: Anti-PA IgG test is highly accurate to detect chronic PA infection in bronchiectasis patients. In addition, it may be a marker of disease severity and treatment response.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Bronchiectasis; Chronic infection; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2017        PMID: 28610665     DOI: 10.1016/j.rmed.2017.05.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

1.  Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors.

Authors:  Simon Leiris; David T Davies; Nicolas Sprynski; Jérôme Castandet; Lilha Beyria; Michael S Bodnarchuk; Jonathan M Sutton; Toby M G Mullins; Mark W Jones; Andrew K Forrest; T David Pallin; Paduri Karunakar; Sathish Kumar Martha; Battu Parusharamulu; Ramesh Ramula; Venkatesh Kotha; Narender Pottabathini; Srinivasu Pothukanuri; Marc Lemonnier; Martin Everett
Journal:  ACS Med Chem Lett       Date:  2021-01-15       Impact factor: 4.345

2.  Antibiogram profile and virulence signatures of Pseudomonas aeruginosa isolates recovered from selected agrestic hospital effluents.

Authors:  Q Mapipa; T O Digban; N E Nnolim; U U Nwodo
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

3.  Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease.

Authors:  Fathia G Jaat; Sajidah F Hasan; Audrey Perry; Sharon Cookson; Santosh Murali; John D Perry; Clare V Lanyon; Anthony De Soyza; Stephen M Todryk
Journal:  Respir Res       Date:  2018-05-30

4.  Disarming Pseudomonas aeruginosa Virulence by the Inhibitory Action of 1,10-Phenanthroline-5,6-Dione-Based Compounds: Elastase B (LasB) as a Chemotherapeutic Target.

Authors:  Anna Clara M Galdino; Lívia Viganor; Alexandre A de Castro; Elaine F F da Cunha; Thaís P Mello; Larissa M Mattos; Marcos D Pereira; Mary C Hunt; Megan O'Shaughnessy; Orla Howe; Michael Devereux; Malachy McCann; Teodorico C Ramalho; Marta H Branquinha; André L S Santos
Journal:  Front Microbiol       Date:  2019-08-02       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.